Trials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.

Novogen (ASX:NRT) has cited a "voting systems error" as the reason why a significant number of proxy votes were cast against the resolution to adopt the company's remuneration report for the year ended June 30 at its AGM in late October.

The Australian Securities and Investments Commission has written to Novogen (ASX:NRT) after the company adopted the company's remuneration report based on a show of hands at its AGM in late October, despite receiving an overwhelming majority of proxies against the resolution.

Australian pharma Novogen has received further positive news from a US trial of its experimental cancer-resensitising agent phenoxodiol.

Biopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial.

Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.

Pharmaceutical company Novogen (ASX:NRT) saw revenues of AUD$17.7 million for 2004-05, a 7.5 per cent increase on the previous year, and a net loss of $11.1 million.

A phase II trial conducted by Novogen (ASX:NRT) subsidiary Glycotex has found that its wound healing compound Glucoprime promotes healing in venous stasis ulcers.

Biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 is set to enter Phase I trials at the Gold Coast Hospital.

ChemGenex Pharmaceuticals (ASX:CXS) has received approval to list on the NASDAQ SmallCap Market under the ticker CXSP.

Sydney oncology drug developer Novogen (ASX:NRT, NASDAQ:NVGN) can smell the clover across the width of the Pacific, after its Connecticut-based subsidiary Marshall Edwards (LSE AIM:MSH and NASDAQ:MSHL) reported outstanding preliminary results from a trial of its clover-derived cancer drug phenoxodiol.